WO2022106984A3 - Small molecule inhibitors of sars-cov2 main protease - Google Patents

Small molecule inhibitors of sars-cov2 main protease Download PDF

Info

Publication number
WO2022106984A3
WO2022106984A3 PCT/IB2021/060572 IB2021060572W WO2022106984A3 WO 2022106984 A3 WO2022106984 A3 WO 2022106984A3 IB 2021060572 W IB2021060572 W IB 2021060572W WO 2022106984 A3 WO2022106984 A3 WO 2022106984A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov2
sars
small molecule
molecule inhibitors
main protease
Prior art date
Application number
PCT/IB2021/060572
Other languages
French (fr)
Other versions
WO2022106984A2 (en
Inventor
Oleksandr Buzko
J. Gardner NELSON
Original Assignee
Nantcell, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantcell, Inc. filed Critical Nantcell, Inc.
Publication of WO2022106984A2 publication Critical patent/WO2022106984A2/en
Publication of WO2022106984A3 publication Critical patent/WO2022106984A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

Disclosed are therapeutic compositions for the prevention, amelioration and/or treatment of infectious disease, including, but not limited to, SARS-COV2.
PCT/IB2021/060572 2020-11-18 2021-11-15 Small molecule inhibitors of sars-cov2 main protease WO2022106984A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063115461P 2020-11-18 2020-11-18
US63/115,461 2020-11-18

Publications (2)

Publication Number Publication Date
WO2022106984A2 WO2022106984A2 (en) 2022-05-27
WO2022106984A3 true WO2022106984A3 (en) 2022-07-07

Family

ID=78827896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/060572 WO2022106984A2 (en) 2020-11-18 2021-11-15 Small molecule inhibitors of sars-cov2 main protease

Country Status (1)

Country Link
WO (1) WO2022106984A2 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D.L. MCKEE, ET AL.: "Candidate drugs against SARS-CoV-2 and COVID-19", PHARMACOLOGICAL RESEARCH, vol. 157, 104859, 29 April 2020 (2020-04-29), Elsevier, Oxford, GB, XP086154221, ISSN: 1043-6618, DOI: 10.1016/j.phrs.2020.104859 *
LU ZHENG, ET AL.: "Potential treatment methods targeting 2019-nCoV infection", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 205, 112687, 28 July 2020 (2020-07-28), Elsevier Masson, Paris, FR, XP086277986, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.112687 *

Also Published As

Publication number Publication date
WO2022106984A2 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
MX2022015812A (en) Inhibitors of cysteine proteases and methods of use thereof.
MX2021009246A (en) Immunomodulators, compositions and methods thereof.
MX2021001186A (en) Purinones as ubiquitin-specific protease 1 inhibitors.
MX2022015272A (en) Inhibitors of kras g12c protein and uses thereof.
CA2747703C (en) Compositions and methods for the treatment or the prevention of infections by e. coli
AU2012332832A8 (en) Compositions useful for the treatment of viral diseases
MX2022014007A (en) Compounds as bcl-2 inhibitors.
MX2022001004A (en) Enzyme inhibitors.
MX2022002740A (en) Il-2 conjugates and methods of use to treat autoimmune diseases.
EP4342473A3 (en) Compounds useful in hiv therapy
MX2023002233A (en) Phospholipid compounds and uses thereof.
MX2021014558A (en) Treatments of angioedema.
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2023001296A (en) Compositions and methods for treating diseases and disorders.
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
BR112022000505A2 (en) N-substituted 3,4-(5-fused-ring)-5-phenyl-pyrrolidin-2-one compounds as isoqc and/or qc enzyme inhibitors
WO2023086220A3 (en) Papd5 inhibitors and methods of use thereof
MX2022000712A (en) Nlrp3 modulators.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
MX2023003675A (en) Hsd17b13 inhibitors and uses thereof.
AU2016245434A8 (en) Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto
MX2022011576A (en) Nlrp3 modulators.
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
WO2022106984A3 (en) Small molecule inhibitors of sars-cov2 main protease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21823364

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21823364

Country of ref document: EP

Kind code of ref document: A2